Pharmaceutical company AstraZeneca has committed to the largest private capital investment seen in Maryland in the last decade.
The company recently announced plans to significantly expand its biologics manufacturing facility in Frederick County, and also construct a new state-of-the-art clinical manufacturing space in Montgomery County.
“It was really the smart decision — to further invest in the state of Maryland and to continue to help this ecosystem thrive.”
Dan Wygal, vice president of U.S. corporate affairs for AstraZeneca, said to the Washington Business Journal.
With more than 5,500 employees in Maryland, the company is expected to boost job creation throughout the Capital Region. Between both Frederick and Gaithersburg locations, an estimated 300 new jobs will be created, as well as an additional 1,900 construction jobs over the next four years.
“Today marks a landmark moment for Maryland and American patients,” said AstraZeneca Chief Executive Officer Pascal Soriot. “As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland—supporting 2,600 jobs, catalysing economic growth and bringing our extensive rare disease portfolio onshore for the first time. This investment strengthens the resilience of the U.S. medicines supply chain and accelerates access to transformative therapies for patients across America and around the world.”
